InflareIBD vs Aidy for Crohn's: One-Time Unlock or Free?

InflareIBD's listing describes offline, IBD-specific iPhone tracking. InflareIBD's listing claims free offline basics and a $3.99 report unlock. Aidy supplies a broader Crohn's workflow spanning daily logs, treatment, disease activity, and education.

Quick answer: For most people with Crohn's, choose Aidy for free treatment-aware logging, biologic schedules, modified HBI trends, reports, and education. InflareIBD is the genuine exception for its advertised local-only storage, customizable colonoscopy checklist, or $3.99 report unlock.

Decision factor	Aidy	InflareIBD (public claims)
Best for	Complete Crohn's record	Claims local-only logging
Daily IBD record	Symptoms, stool, food, treatment	Claims check-ins, food, medicine, adherence
Treatment tools	Detailed biologic schedules	Claims infusion reminder and checklist
Reports and insights	Modified HBI and reports	Claims paid charts and PDF
Access and cost	Free	Claims free basics and $3.99 Pro
Overall pick	Aidy	Local-privacy exception

Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.

InflareIBD has a simple $3.99 unlock boundary

An InflareIBD review should distinguish the free tools from the paid layer. The current listing says daily check-ins, food logging, medication and adherence tracking, an infusion reminder, and a procedure-preparation checklist remain free. It prices the single InflareIBD Pro purchase at $3.99 and says it removes limits on history while adding trend charts and a provider-ready PDF export. Apple shows no subscription product.

The app is very new. Apple's listing dates its launch to May 27, 2026, shows version 1.1 four days later, displays no ratings, requires iOS 17, and describes it as designed for iPhone. That brief history makes long-term reliability and support difficult to assess.

There is also an advertising inconsistency. The main description promises no ads, while the version 1.1 notes say optional ads were added and Premium makes the app ad-free (App Store). The $3.99 InflareIBD price is unusually clear, but the free experience should be checked on the current build.

Food patterns and procedure planning are thoughtfully restrained

InflareIBD’s listing describes a neutral food co-occurrence view that helps users see which foods appeared near logged changes without declaring a cause. That restraint aligns with NIDDK guidance: researchers have not found that specific foods cause or worsen Crohn’s symptoms, while a food diary may help identify personal associations (NIDDK). Aidy offers food photos or descriptions and personalized food-symptom correlations, with the same need for careful interpretation.

As a colonoscopy checklist app, InflareIBD claims to address a real short-term task. It says users can enter the clinician’s own preparation steps and receive a countdown to the procedure. The American Society for Gastrointestinal Endoscopy advises following the doctor’s exact dose and timing instructions because preparation options vary (ASGE). A customizable checklist can help organize those directions, but it should never supply or alter them.

InflareIBD also claims users can configure an infusion reminder from a prescription. That makes it a useful minimalist Crohn's infusion reminder app for an established recurring date.

Aidy gives treatment events more Crohn’s context

Aidy’s biologic workflow goes beyond a manually entered reminder. It includes named biologics and biosimilars, induction and maintenance schedules, live dose countdowns, injection-site rotation, route or interval changes, adherence views, and check-ins after injections or infusions. Crohn’s treatment can include corticosteroids, immunosuppressants, biologics, small-molecule medicine, nutrition support, or surgery, depending on the person (NIDDK). Aidy’s treatment tools reflect more of that continuing organization.

The same timeline connects common and custom symptoms, Bristol stool entries, meals, medication, and a modified Harvey-Bradshaw Index (HBI). HBI remains prominent in clinical practice and pragmatic trials, although patient-reported estimation has limitations (PubMed). InflareIBD’s public description does not identify HBI, named biologic schedules, induction phases, injection-site rotation, post-dose tolerability, or an educational layer.

Both can produce care-team material, but InflareIBD’s listing says its PDF and complete history require Pro. Aidy connects its reports to symptoms, stool, food, adherence, treatment changes, and HBI trends. That makes Aidy the more complete InflareIBD alternative for longitudinal Crohn’s preparation.

Privacy favors InflareIBD, while overall fit favors Aidy

InflareIBD says everything stays on the device, with no account, cloud sync, or data sharing. Apple’s developer-reported privacy label says “Data Not Collected.” This design minimizes outside handling and makes the app attractive for sensitive records. It also leaves cross-device access and recovery dependent on the phone and the user’s backup practices. Aidy uses an account-connected service and Apple’s label says health and other data may be linked to identity, so InflareIBD has the clearer privacy advantage.

Neither diary can establish whether inflammation is active. AGA recommends combining symptoms with biomarkers in multiple Crohn’s monitoring situations (AGA). NIDDK explains that assessment may include blood tests, stool tests, endoscopy, and imaging (NIDDK). App trends can organize a discussion; treatment and procedure decisions remain clinical work.

Aidy is free, has no paid patient subscriptions, and runs no ads. Its complete Crohn's treatment and reporting workflow is available without a purchase. InflareIBD claims the stronger local-only model. Aidy remains the better primary Crohn’s companion because detailed biologic logistics, daily inputs, HBI trends, reports, and source-backed education stay connected.